RECRUITINGPhase 2 / Phase 3INTERVENTIONAL
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
About This Trial
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Who Should NOT Join This Trial:
- Prior incisional glaucoma surgery in the study eye
- Prior argon laser trabeculoplasty (ALT) in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Exclusion Criteria:
* Prior incisional glaucoma surgery in the study eye
* Prior argon laser trabeculoplasty (ALT) in the study eye
* Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Treatments Being Tested
DRUG
Gen 2 Travoprost Intracameral Implant
travoprost
DRUG
Timolol eye drops 0.5%
timolol 0.5%
PROCEDURE
Sham Procedure
sham implant administration
OTHER
Placebo eye drops
artificial tears
Locations (3)
Glaukos Investigative Site
Grand Junction, Colorado, United States
Glaukos Investigative Site
Oklahoma City, Oklahoma, United States
Glaukos Clinical Site
El Paso, Texas, United States